Distribution of nitroreductive activity toward nilutamide in rat.

[1]  M. Lag,et al.  Polycyclic aromatic hydrocarbons induce both apoptotic and anti-apoptotic signals in Hepa1c1c7 cells. , 2003, Carcinogenesis.

[2]  J. Boucher,et al.  Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug. , 2003, Chemical research in toxicology.

[3]  V. Arlt,et al.  Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome p450 reductase. , 2003, Cancer research.

[4]  R. T. Miller.  Dinitrobenzene-mediated production of peroxynitrite by neuronal nitric oxide synthase. , 2002, Chemical research in toxicology.

[5]  M. Miller,et al.  1,3-Dinitrobenzene metabolism and protein binding. , 2002, Chemical research in toxicology.

[6]  D. Saur,et al.  Site-specific gene expression of nNOS variants in distinct functional regions of rat gastrointestinal tract. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[7]  H. Yamazaki,et al.  Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay. , 2001, Mutation research.

[8]  R. Banerjee,et al.  Human Methionine Synthase Reductase, a Soluble P-450 Reductase-like Dual Flavoprotein, Is Sufficient for NADPH-dependent Methionine Synthase Activation* , 2001, The Journal of Biological Chemistry.

[9]  C. Kasper,et al.  NADPH-Cytochrome P450 Oxidoreductase , 2001, The Journal of Biological Chemistry.

[10]  A. Rauth,et al.  Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia. , 2000, Biochemical pharmacology.

[11]  C. Wolf,et al.  Cloning and Characterization of a Novel Human Dual Flavin Reductase* , 2000, The Journal of Biological Chemistry.

[12]  P. Ortiz de Montellano,et al.  Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. , 1999, Cancer research.

[13]  D. Saur,et al.  Characterization and splice variants of neuronal nitric oxide synthase in rat small intestine. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[14]  I. Lambert,et al.  Oxygen-Insensitive Nitroreductases: Analysis of the Roles ofnfsA and nfsB in Development of Resistance to 5-Nitrofuran Derivatives in Escherichia coli , 1998, Journal of bacteriology.

[15]  T. Sofuni,et al.  Purification and Characterization of Wild-type and Mutant “Classical” Nitroreductases of Salmonella typhimurium , 1998, The Journal of Biological Chemistry.

[16]  Aaron D. Wilson,et al.  Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Castro,et al.  Rat liver nuclear nifurtimox nitroreductase activity. , 1997, Research communications in molecular pathology and pharmacology.

[18]  P. Workman,et al.  Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554). , 1997, Biochemical pharmacology.

[19]  K. Pritchard,et al.  Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. , 1997, Biochemistry.

[20]  B. Masters,et al.  Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Garofalo,et al.  Erythrocyte enzymes catalyze 1-nitropyrene and 3-nitrofluoranthene nitroreduction. , 1996, Toxicology.

[22]  H. Barham,et al.  Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase. , 1996, Biochemical pharmacology.

[23]  R. Johns,et al.  Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. , 1996, The American journal of physiology.

[24]  B. Masters,et al.  Nitric oxide synthases: analogies to cytochrome P450 monooxygenases and characterization of recombinant rat neuronal nitric oxide synthase hemoprotein. , 1996, Methods in enzymology.

[25]  F. Doermann,et al.  [Fatal fulminating hepatitis caused by nilutamide. A new case]. , 1996, Gastroenterologie clinique et biologique.

[26]  U. Förstermann,et al.  Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. , 1995, Biochemical pharmacology.

[27]  A. Begleiter,et al.  Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro. , 1995, Biochemical pharmacology.

[28]  Yukitaka Ushio,et al.  Immunohistochemical expression of inducible nitric oxide synthase (iNOS) in reversible endotoxic shock studied by a novel monoclonal antibody against rat iNOS , 1995, Journal of leukocyte biology.

[29]  R. Bos,et al.  Nitroreduction and formation of hemoglobin adducts in rats with a human intestinal microflora. , 1994, Environmental health perspectives.

[30]  W. Bechtold,et al.  Metabolism of nitrofluoranthenes by rat lung subcellular fractions. , 1993, Carcinogenesis.

[31]  C. Lowenstein,et al.  Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Degott,et al.  Hépatite fulminante mortelle imputable au nilutamide (Anandron). , 1993 .

[33]  F. Friedlos,et al.  The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). , 1992, Biochemical pharmacology.

[34]  D. Pessayre,et al.  Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. , 1992, The Journal of pharmacology and experimental therapeutics.

[35]  P. Pfitzenmeyer,et al.  Nilutamide pneumonitis: a report on eight patients. , 1992, Thorax.

[36]  P. Klatt,et al.  Ca2+/calmodulin-dependent cytochrome c reductase activity of brain nitric oxide synthase. , 1992, The Journal of biological chemistry.

[37]  D. Pessayre,et al.  Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. , 1992, Biochemical pharmacology.

[38]  P. Foucher,et al.  Pharmacokinetics and metabolism of nilutamide in the isolated rat lung. , 1991, The Journal of pharmacology and experimental therapeutics.

[39]  P. Howard,et al.  Kinetics and cofactor requirements for the nitroreductive metabolism of 1-nitropyrene and 3-nitrofluoranthene by rabbit liver aldehyde oxidase. , 1991, Carcinogenesis.

[40]  S. Snyder,et al.  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase , 1991, Nature.

[41]  D. Pessayre,et al.  Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. , 1991, The Journal of pharmacology and experimental therapeutics.

[42]  G. Winston,et al.  Dinitropyrene nitroreductase activity of purified NAD(P)H-quinone oxidoreductase: role in rat liver cytosol and induction by Aroclor-1254 pretreatment. , 1991, Carcinogenesis.

[43]  H. Fuse,et al.  [Clinical study of RU 23908 (nilutamide) in prostatic cancer]. , 1991, Hinyokika kiyo. Acta urologica Japonica.

[44]  L. Pendyala,et al.  Pharmacokinetics and metabolismof nilutamide , 1991 .

[45]  M. Ducreux,et al.  [Nilutamide-induced acute hepatitis]. , 1991, Gastroenterologie clinique et biologique.

[46]  P. Howard,et al.  The kinetics of 1-nitropyrene and 3-nitrofluoranthene metabolism using bovine liver xanthine oxidase. , 1990, Cancer letters.

[47]  C. Cerniglia,et al.  Metabolism of 1-, 3-, and 6-nitrobenzo[a]pyrene by intestinal microflora. , 1988, Journal of toxicology and environmental health.

[48]  G. L. Kedderis,et al.  The metabolic activation of nitroheterocyclic therapeutic agents. , 1988, Drug metabolism reviews.

[49]  P. Workman,et al.  Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. , 1987, Biochemical pharmacology.

[50]  Y. Ohnishi,et al.  Metabolic Activation of 1–Nitropyrene and 1, 6–Dinitropyrene by Nitroreductases from Bacteroides fragilis and Distribution of Nitroreductase Activity in Rats , 1986, Microbiology and immunology.

[51]  G. Adams,et al.  Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview. , 1986, Biochemical pharmacology.

[52]  P. Workman,et al.  Benznidazole: nitroreduction and inhibition of cytochrome P-450 in chemosensitization of tumour response to cytotoxic drugs. , 1986, Biochemical pharmacology.

[53]  J. A. Bond,et al.  Contribution of intestinal microfloral metabolism to the total macromolecular covalent binding of 1-nitro-pyrene in the lung and liver of the rat. , 1985, Toxicology.

[54]  J. A. Bond,et al.  Metabolism of 1-[14C]nitropyrene in respiratory tract tissue of rats exposed to diesel exhaust. , 1985, Toxicology and applied pharmacology.

[55]  J. Castro,et al.  Reductive metabolism and activation of benznidazole. , 1984, Biochemical pharmacology.

[56]  R. Remmel,et al.  Role of the intestinal microflora in clonazepam metabolism in the rat. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[57]  M. Boyd,et al.  METABOLIC ACTIVATION AS A BASIS FOR ORGAN‐SELECTIVE TOXICITY , 1983, Clinical and experimental pharmacology & physiology.

[58]  J. Fisher,et al.  Reductive drug metabolism. , 1983, Drug metabolism reviews.

[59]  E. Mimnaugh,et al.  Activation of pharmacologic agents to radical intermediates. Implications for the role of free radicals in drug action and toxicity. , 1982, Biochemical pharmacology.

[60]  Y. Ohnishi,et al.  Biotransformation of 1‐Nitropyrene in Intestinal Anaerobic Bacteria , 1982, Microbiology and immunology.

[61]  G. Bryan,et al.  Nitroreduction of 5-nitrofuran derivatives by rat liver xanthine oxidase and reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase. , 1974, Biochemical pharmacology.

[62]  M. Wolpert,et al.  Nitroreductase activity of mammalian liver aldehyde oxidase. , 1973, The Journal of pharmacology and experimental therapeutics.

[63]  J. Gillette,et al.  Reduction of niridazole by rat liver santhine oxidase. , 1971, Biochemical pharmacology.